In this episode, we’re talking money.
The guests in this discussion recognize that the economic climate has been different (and more chaotic) in last three to four months, but expect a steady but slow improvement as we move into the new year.
This episode reviews 2024’s investment landscape and the policies influencing investment going into 2025.
 
Host
<a href="https://www.linkedin.com/in/lorielliskatz/" rel="ugc noopener noreferrer" target="_blank">⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠</a>, Head of Insights, BioSpace
 
Guests
<a href="https://www.linkedin.com/in/konstantina-katcheves-3757236/" rel="ugc noopener noreferrer" target="_blank">Konstantina Katcheves</a>, Senior Vice President, Innovative Medicines Global Business Development and Acquisitions, Teva Pharmaceuticals
<a href="https://www.linkedin.com/in/sanskritithakur/" rel="ugc noopener noreferrer" target="_blank">Sanskriti Thakur</a>, Chairwoman, TOWER Capital

Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.